Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383 9. 395. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investi- gators. N Engl J Med. 1996;335:1001 9. 396. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cho- lesterol levels. The Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349 57. 397. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorva- statin versus Revascularization Treatment Investigators. N Engl J Med. 1999;341:70 6. 398. MRC-BHF Heart Protection Study of cholesterol lowering with sim- vastatin in 20,536 high-risk individuals: a randomised placebocon- trolled trial. Lancet. 2002;360:7 22. 399. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20 8. 400. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425 35. 401. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med. 2004; 164:1427 36. 402. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:489 97. 403. Hebert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med. 1993;153:578 81. 404. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. 